Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
4
CSLLY Quote, Financials, Valuation and Earnings
Last price:
$52.11
Seasonality move
:
0.58%
Day range:
$51.85 - $52.28
52-week range:
$50.85 - $89.71
Dividend yield:
2.8%
P/E ratio:
36.28x
P/S ratio:
3.31x
P/B ratio:
4.51x
Volume:
94.5K
Avg. volume:
159.6K
1-year change:
-35.4%
Market cap:
$50.6B
Revenue:
$15.4B
EPS (TTM):
$1.44
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CSLLY
CSL Ltd.
|
-- | -- | -- | -- | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | $11.00 |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | $9.50 |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -- | -- | $18.94 |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
-- | -- | -- | -- | -- |
|
SPHRY
Starpharma Holdings Ltd.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CSLLY
CSL Ltd.
|
$52.11 | -- | $50.6B | 36.28x | $0.81 | 2.8% | 3.31x |
|
ATHE
Alterity Therapeutics Ltd.
|
$3.44 | $11.00 | $62.4M | -- | $0.00 | 0% | 3.58x |
|
IMMP
Immutep Ltd.
|
$2.80 | $9.50 | $407.6M | -- | $0.00 | 0% | 153.33x |
|
KZIA
Kazia Therapeutics Ltd.
|
$8.45 | $18.94 | $95.8M | -- | $0.00 | 0% | 381.81x |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
$0.0079 | -- | $13.3M | -- | $0.00 | 0% | 0.14x |
|
SPHRY
Starpharma Holdings Ltd.
|
$3.15 | -- | $131.7M | -- | $0.00 | 0% | 14.62x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CSLLY
CSL Ltd.
|
39.2% | -0.064 | -- | 0.84x |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | 2.224 | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | 0.527 | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-6.76% | 4.448 | 5.57% | 0.07x |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
-- | -3.348 | -- | -- |
|
SPHRY
Starpharma Holdings Ltd.
|
9.65% | 3.556 | -- | 4.93x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CSLLY
CSL Ltd.
|
$4.3B | $2B | 8.85% | 14.06% | 33.52% | -- |
|
ATHE
Alterity Therapeutics Ltd.
|
-- | -- | -- | -- | -- | -- |
|
IMMP
Immutep Ltd.
|
-- | -- | -- | -- | -- | -- |
|
KZIA
Kazia Therapeutics Ltd.
|
-- | -- | -784.09% | -1083.16% | -- | -- |
|
LVCLF
Algorae Pharmaceuticals Ltd.
|
-- | -- | -- | -- | -- | -- |
|
SPHRY
Starpharma Holdings Ltd.
|
-- | -- | -40.48% | -43.48% | -- | -- |
CSL Ltd. vs. Competitors
-
Which has Higher Returns CSLLY or ATHE?
Alterity Therapeutics Ltd. has a net margin of 24.44% compared to CSL Ltd.'s net margin of --. CSL Ltd.'s return on equity of 14.06% beat Alterity Therapeutics Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL Ltd.52.1% $2.07 $32.5B ATHEAlterity Therapeutics Ltd.-- -- -- -
What do Analysts Say About CSLLY or ATHE?
CSL Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Alterity Therapeutics Ltd. has an analysts' consensus of $11.00 which suggests that it could grow by 219.68%. Given that Alterity Therapeutics Ltd. has higher upside potential than CSL Ltd., analysts believe Alterity Therapeutics Ltd. is more attractive than CSL Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL Ltd.0 0 0 ATHEAlterity Therapeutics Ltd.1 0 0 -
Is CSLLY or ATHE More Risky?
CSL Ltd. has a beta of 0.771, which suggesting that the stock is 22.939% less volatile than S&P 500. In comparison Alterity Therapeutics Ltd. has a beta of 0.114, suggesting its less volatile than the S&P 500 by 88.643%.
-
Which is a Better Dividend Stock CSLLY or ATHE?
CSL Ltd. has a quarterly dividend of $0.81 per share corresponding to a yield of 2.8%. Alterity Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL Ltd. pays 43.93% of its earnings as a dividend. Alterity Therapeutics Ltd. pays out -- of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or ATHE?
CSL Ltd. quarterly revenues are $8.2B, which are larger than Alterity Therapeutics Ltd. quarterly revenues of --. CSL Ltd.'s net income of $2B is higher than Alterity Therapeutics Ltd.'s net income of --. Notably, CSL Ltd.'s price-to-earnings ratio is 36.28x while Alterity Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL Ltd. is 3.31x versus 3.58x for Alterity Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL Ltd.3.31x 36.28x $8.2B $2B ATHEAlterity Therapeutics Ltd.3.58x -- -- --
-
Which has Higher Returns CSLLY or IMMP?
Immutep Ltd. has a net margin of 24.44% compared to CSL Ltd.'s net margin of --. CSL Ltd.'s return on equity of 14.06% beat Immutep Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL Ltd.52.1% $2.07 $32.5B IMMPImmutep Ltd.-- -- -- -
What do Analysts Say About CSLLY or IMMP?
CSL Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Immutep Ltd. has an analysts' consensus of $9.50 which suggests that it could grow by 239.29%. Given that Immutep Ltd. has higher upside potential than CSL Ltd., analysts believe Immutep Ltd. is more attractive than CSL Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL Ltd.0 0 0 IMMPImmutep Ltd.1 0 0 -
Is CSLLY or IMMP More Risky?
CSL Ltd. has a beta of 0.771, which suggesting that the stock is 22.939% less volatile than S&P 500. In comparison Immutep Ltd. has a beta of 1.756, suggesting its more volatile than the S&P 500 by 75.579%.
-
Which is a Better Dividend Stock CSLLY or IMMP?
CSL Ltd. has a quarterly dividend of $0.81 per share corresponding to a yield of 2.8%. Immutep Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL Ltd. pays 43.93% of its earnings as a dividend. Immutep Ltd. pays out -- of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or IMMP?
CSL Ltd. quarterly revenues are $8.2B, which are larger than Immutep Ltd. quarterly revenues of --. CSL Ltd.'s net income of $2B is higher than Immutep Ltd.'s net income of --. Notably, CSL Ltd.'s price-to-earnings ratio is 36.28x while Immutep Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL Ltd. is 3.31x versus 153.33x for Immutep Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL Ltd.3.31x 36.28x $8.2B $2B IMMPImmutep Ltd.153.33x -- -- --
-
Which has Higher Returns CSLLY or KZIA?
Kazia Therapeutics Ltd. has a net margin of 24.44% compared to CSL Ltd.'s net margin of --. CSL Ltd.'s return on equity of 14.06% beat Kazia Therapeutics Ltd.'s return on equity of -1083.16%.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL Ltd.52.1% $2.07 $32.5B KZIAKazia Therapeutics Ltd.-- -- -$6.3M -
What do Analysts Say About CSLLY or KZIA?
CSL Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Kazia Therapeutics Ltd. has an analysts' consensus of $18.94 which suggests that it could grow by 124.09%. Given that Kazia Therapeutics Ltd. has higher upside potential than CSL Ltd., analysts believe Kazia Therapeutics Ltd. is more attractive than CSL Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL Ltd.0 0 0 KZIAKazia Therapeutics Ltd.1 0 0 -
Is CSLLY or KZIA More Risky?
CSL Ltd. has a beta of 0.771, which suggesting that the stock is 22.939% less volatile than S&P 500. In comparison Kazia Therapeutics Ltd. has a beta of 1.775, suggesting its more volatile than the S&P 500 by 77.474%.
-
Which is a Better Dividend Stock CSLLY or KZIA?
CSL Ltd. has a quarterly dividend of $0.81 per share corresponding to a yield of 2.8%. Kazia Therapeutics Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL Ltd. pays 43.93% of its earnings as a dividend. Kazia Therapeutics Ltd. pays out -- of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or KZIA?
CSL Ltd. quarterly revenues are $8.2B, which are larger than Kazia Therapeutics Ltd. quarterly revenues of --. CSL Ltd.'s net income of $2B is higher than Kazia Therapeutics Ltd.'s net income of --. Notably, CSL Ltd.'s price-to-earnings ratio is 36.28x while Kazia Therapeutics Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL Ltd. is 3.31x versus 381.81x for Kazia Therapeutics Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL Ltd.3.31x 36.28x $8.2B $2B KZIAKazia Therapeutics Ltd.381.81x -- -- --
-
Which has Higher Returns CSLLY or LVCLF?
Algorae Pharmaceuticals Ltd. has a net margin of 24.44% compared to CSL Ltd.'s net margin of --. CSL Ltd.'s return on equity of 14.06% beat Algorae Pharmaceuticals Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL Ltd.52.1% $2.07 $32.5B LVCLFAlgorae Pharmaceuticals Ltd.-- -- -- -
What do Analysts Say About CSLLY or LVCLF?
CSL Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Algorae Pharmaceuticals Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that CSL Ltd. has higher upside potential than Algorae Pharmaceuticals Ltd., analysts believe CSL Ltd. is more attractive than Algorae Pharmaceuticals Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL Ltd.0 0 0 LVCLFAlgorae Pharmaceuticals Ltd.0 0 0 -
Is CSLLY or LVCLF More Risky?
CSL Ltd. has a beta of 0.771, which suggesting that the stock is 22.939% less volatile than S&P 500. In comparison Algorae Pharmaceuticals Ltd. has a beta of -0.656, suggesting its less volatile than the S&P 500 by 165.606%.
-
Which is a Better Dividend Stock CSLLY or LVCLF?
CSL Ltd. has a quarterly dividend of $0.81 per share corresponding to a yield of 2.8%. Algorae Pharmaceuticals Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL Ltd. pays 43.93% of its earnings as a dividend. Algorae Pharmaceuticals Ltd. pays out -- of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or LVCLF?
CSL Ltd. quarterly revenues are $8.2B, which are larger than Algorae Pharmaceuticals Ltd. quarterly revenues of --. CSL Ltd.'s net income of $2B is higher than Algorae Pharmaceuticals Ltd.'s net income of --. Notably, CSL Ltd.'s price-to-earnings ratio is 36.28x while Algorae Pharmaceuticals Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL Ltd. is 3.31x versus 0.14x for Algorae Pharmaceuticals Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL Ltd.3.31x 36.28x $8.2B $2B LVCLFAlgorae Pharmaceuticals Ltd.0.14x -- -- --
-
Which has Higher Returns CSLLY or SPHRY?
Starpharma Holdings Ltd. has a net margin of 24.44% compared to CSL Ltd.'s net margin of --. CSL Ltd.'s return on equity of 14.06% beat Starpharma Holdings Ltd.'s return on equity of -43.48%.
Company Gross Margin Earnings Per Share Invested Capital CSLLYCSL Ltd.52.1% $2.07 $32.5B SPHRYStarpharma Holdings Ltd.-- -- $15.9M -
What do Analysts Say About CSLLY or SPHRY?
CSL Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Starpharma Holdings Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that CSL Ltd. has higher upside potential than Starpharma Holdings Ltd., analysts believe CSL Ltd. is more attractive than Starpharma Holdings Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSLLYCSL Ltd.0 0 0 SPHRYStarpharma Holdings Ltd.0 0 0 -
Is CSLLY or SPHRY More Risky?
CSL Ltd. has a beta of 0.771, which suggesting that the stock is 22.939% less volatile than S&P 500. In comparison Starpharma Holdings Ltd. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.401%.
-
Which is a Better Dividend Stock CSLLY or SPHRY?
CSL Ltd. has a quarterly dividend of $0.81 per share corresponding to a yield of 2.8%. Starpharma Holdings Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSL Ltd. pays 43.93% of its earnings as a dividend. Starpharma Holdings Ltd. pays out -- of its earnings as a dividend. CSL Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSLLY or SPHRY?
CSL Ltd. quarterly revenues are $8.2B, which are larger than Starpharma Holdings Ltd. quarterly revenues of --. CSL Ltd.'s net income of $2B is higher than Starpharma Holdings Ltd.'s net income of --. Notably, CSL Ltd.'s price-to-earnings ratio is 36.28x while Starpharma Holdings Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSL Ltd. is 3.31x versus 14.62x for Starpharma Holdings Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSLLYCSL Ltd.3.31x 36.28x $8.2B $2B SPHRYStarpharma Holdings Ltd.14.62x -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Buy
57
SEZL alert for Feb 28
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
